Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel treatments for familial hypercholesterolemia: pharmacogenetics at work.

Pharmacotherapy - 1 Sept 2014

Marbach Jeffrey A, McKeon Jessica L, Ross Joyce L, Duffy Danielle

Abstract excerpt

The familial hypercholesterolemias (FHs) are inherited disorders of lipoprotein metabolism that are among the most prevalent genetically inherited disorders. Various genetic mutations ultimately lead to greatly increased low-density lipoprotein-cholesterol (LDL-C) levels over a lifetime. Consequently, patients with FH develop coronary artery disease at significantly earlier ages and at a greater frequency than...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticholesteremic Agents
Share to Benzimidazoles
Share to Cholesterol, LDL

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Design

Share to Hyperlipoproteinemia Type II

Share to Mutation

Share to Oligonucleotides

Share to Pharmacogenetics

Source

Identifiers

PMID: 24899514
DOI: 10.1002/phar.1441

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel treatments for familial hypercholesterolemia: pharmacogenetics at work.PMID 24899514Read ↗

My Approach to the Patient With Familial Hypercholesterolemia.Semantic proximity Read ↗

Mipomersen: evidence-based review of its potential in the treatment of homozygous and severe heterozygous familial hypercholesterolemiaSemantic proximity Read ↗

Familial hypercholesterolaemia.Semantic proximity Read ↗

Mipomersen and lomitapide: Two new drugs for the treatment of homozygous familial hypercholesterolemia.Semantic proximity Read ↗

From physiopathology to treatment of familial hypercholesterolemia: Existing and emerging pharmacotherapies.Semantic proximity Read ↗

Emerging LDL therapies: Using human genetics to discover new therapeutic targets for plasma lipidsSemantic proximity Read ↗

The severe hypercholesterolemia phenotype: clinical diagnosis, management, and emerging therapies.Semantic proximity Read ↗

What is new in familial hypercholesterolemia?Semantic proximity Read ↗

Recent advances in the understanding and care of familial hypercholesterolaemia: significance of the biology and therapeutic regulation of proprotein convertase subtilisin/kexin type 9.Semantic proximity Read ↗

New Approaches in Detection and Treatment of Familial Hypercholesterolemia.Semantic proximity Read ↗

Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives.Semantic proximity Read ↗

Familial hypercholesterolemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.